Dir, 10%
Helen Susan Kim is a Senior Managing Director at Vida Ventures, LLC, a venture capital firm, a position she has held since April 2019.[[5]](https://www.prothena.com/management/helen-kim/)[[7]](https://firstwordpharma.com/story/7052354) She serves as a Director and 10% Owner of Aktis Oncology, Inc. (AKTS), where she has been on the board since 2021, recently purchasing 835,000 shares on January 12, 2026, at $18.00 per share, increasing her stake to approximately 5,671,825 shares valued at over $102 million.[[1]](https://www.gurufocus.com/insider/32411/helen-susan-kim)[[2]](https://whalewisdom.com/filing/kim-helen-susan-4-2026-01-12-170010-0500-akts)[[3]](https://www.aktisoncology.com/our-team/)[[4]](https://www.marketbeat.com/instant-alerts/insider-buying-aktis-oncology-nasdaqakts-director-purchases-835000-shares-of-stock-2026-01-12/) Kim holds an MBA from the University of Chicago and a B.S. in Chemical Engineering from Northwestern University.[[3]](https://www.aktisoncology.com/our-team/)[[5]](https://www.prothena.com/management/helen-kim/)
Her extensive career in biotechnology includes roles as Partner at The Column Group (2018-2019), Executive Vice President of Business Development at Kite Pharma (2014-2018, acquired by Gilead Sciences), Chief Business Officer at NGM Biopharmaceuticals (2009-2012), and CEO and President of Kosan Biosciences, which she restructured before its acquisition by Bristol Myers Squibb in 2008.[[5]](https://www.prothena.com/management/helen-kim/) She previously held senior positions at Affymax, Onyx Pharmaceuticals, Protein Design Labs, and Chiron Corporation, and currently serves on boards including Prothena Corp. Plc (since 2022), ReCode Therapeutics, IconOVir Bio, and others.[[5]](https://www.prothena.com/management/helen-kim/)[[8]](https://www.marketscreener.com/insider/HELEN-KIM-A03AVB/)
View full insider profile →
